ReviewPharmaceuticals (Basel, Switzerland)2025
Targeting the NF-κB Pathway in Cancer: Mechanisms, Resistance, and Therapeutic Potential Across Tumor Types.
Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Anti-proliferative and anti-inflammatory potential of 2-chloro-3-((4-hydroxyphenyl)amino)naphthalene-1,4-dione through targeting TNF-α/IL-8 and NF-κB signaling in HCT116 cancer cells: a comprehensiveBiochemistry and biophysics reports · 2026Article
- Panduratin A Induces Caspase-Dependent Apoptosis and G1-Associated Cell-Cycle Arrest and Enhances TNF-α-Associated Cytotoxicity in NSCLC Cells.Biomolecules · 2026Article
- Crosstalk Between mTOR and NF-κB Signaling Pathways in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2026Article
- Green-Synthesized Silver Nanoparticles fromAntioxidants (Basel, Switzerland) · 2026Article
- Plant-Derived Natural Products and Selective Apoptosis: A Cancer-Cell Vulnerability-State Framework from Redox Imbalance to Membrane-Ion Dysregulation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review).International journal of oncology · 2026Review
- Cannabidiol- and Celecoxib-Loaded Liposomes as a Strategy to Modulate Redox and Inflammatory Signaling in High-Grade Glioma: A Preliminary In Vivo Study.International journal of molecular sciences · 2026Article
- The Inflammation-Mediated Bidirectional Relationship Between Cardiovascular Disease and Cancer.Diseases (Basel, Switzerland) · 2026Review
- CSN3 promotes gastric cancer progression and is associated with immune infiltration and inflammatory signaling.Translational cancer research · 2026Article
- p62/SQSTM1-TRAF6/RIP1 complexes activate NF-κB-mediated PD-L1 expression and promote T-cell apoptosis in MKN45 gastric cancer cells.Journal of gastrointestinal oncology · 2026Article
- Paeonol-Loaded PLGA Nanoparticles Attenuate DMH-Induced Colorectal Carcinogenesis-Associated Oxidative Stress, Inflammation, and Cellular Dysregulation via Modulation of NRF2/HO-1 Signaling in Rats.International journal of molecular sciences · 2026Article
- Vernodalin andBiomedicines · 2026Article
- Metabolic Responses of Melanocytes and Melanoma Cells to UVA Radiation and Phytocannabinoids Exposure.Antioxidants (Basel, Switzerland) · 2026Article
- Experimental and Computational Analysis of Phenolic Acid Association with PAMAM Dendrimers: Comparing Different Formulation Techniques.Polymers · 2026Article
- Loss of p53 Provokes NF-κB-Dependent Disruption of Nucleolar Cap and Nucleoplasmic Redistribution of Fibrillarin During Nucleolar Stress.Biomolecules · 2026Article
- Uncovering Time-DependentMolecules (Basel, Switzerland) · 2026Article
- Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link?International journal of molecular sciences · 2026Review
- Targeted phytotherapy: essential oils, multi-target cancer action & nanodelivery.Frontiers in oncology · 2026Review
- Etiology-Driven Mouse Models of Hepatocellular Carcinoma: Paving the Way for Precision Oncology.Journal of hepatocellular carcinoma · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of death, and current therapeutic options designed to slow the progression of cancer or eradicate cancer cells are often limited by drug resistance, inefficacy, or adverse effects. The Nuclear Factor Kappa B (NF-κB) pathway is a central regulator of inflammation and immune responses, and its dysregulation contributes to cancer development and progression. This review provides an overview of the role of the NF-κB pathway in tumor development and progression and discusses the potential of targeting specific modulators of the pathway for cancer drug discovery, specifically cancers that have the highest prevalence, such as breast, colorectal, lung, melanoma, and prostate cancers. While NF-κB inhibitors show promise, particularly in hematologic malignancies, challenges remain in translating these findings to solid tumors due to pathway complexity and its essential role in normal immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.